2,440 reports of this reaction
2.3% of all GLATIRAMER ACETATE reports
#9 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #9 most commonly reported adverse reaction for GLATIRAMER ACETATE, manufactured by Teva Neuroscience, Inc.. There are 2,440 FDA adverse event reports linking GLATIRAMER ACETATE to INJECTION SITE ERYTHEMA. This represents approximately 2.3% of all 108,384 adverse event reports for this drug.
Patients taking GLATIRAMER ACETATE who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for GLATIRAMER ACETATE, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for GLATIRAMER ACETATE:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 2,440 FDA reports for GLATIRAMER ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 2.3% of all adverse event reports for GLATIRAMER ACETATE, making it a notable side effect.
If you experience injection site erythema while taking GLATIRAMER ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.